- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01541410
Evaluation of the Vascutek Hybrid Graft for Use in the Replacement of the Aortic Arch and Concomitant Treatment of an Aneurysm/Dissection of the Descending Aorta in the Frozen Elephant Trunk Procedure
Study Overview
Status
Intervention / Treatment
Detailed Description
The Vascutek Hybrid device is designed for use during a frozen elephant trunk procedure. Each system is comprised of a fully sealed traditional prosthesis which is stented at the distal end. A minimum of 10 and a maximum of 30 patients with aneurysmal disease of the ascending aorta, the arch and the proximal descending aorta will receive a hybrid prosthesis implanted without the use of the delivery system and a minimum of 10 patients and a maximum of 20 patients will be implanted with a hybrid device using the delivery system.
The traditional prosthesis component is representative of current Gelweave™ product. It is a woven polyester graft, crimped to maintain the lumen and gel coated to ensure that it will seal immediately. The stented section of the graft is a self-expanding endoprosthesis constructed of a thin wall woven polyester and Nitinol ring stents, which are attached to fabric with braided polyester sutures.
The delivery system is a central catheter comprised of a stainless steel braided, Isoplast-Pebax co-extrusion which has been locally strengthened to provide adequate guidewire lumen and sufficient stiffness to deploy the device. The outer sheath is 24Fr extruded PTFE with a groove to provide a localised splitting during deployment. The handle components are moulded in K-Resin & thermoplastic polyurethane to fulfil the functional requirements of the product.
The compacted endoprosthesis is placed through the opened aortic arch and deployed leaving the stented section positioned inside the descending aorta. The device is then released from the delivery system and the handle components removed leaving the full graft in situ and correctly positioned. This allows the surgeon to complete the aortic arch repair as required.
The materials of the endoprosthesis section, and of the traditional prosthesis section of the Hybrid Device are identical to those of current Vascutek product (Anaconda™ Stent Graft System - endoprosthesis; and Gelweave™ - standard vascular graft). All materials used in the delivery system are well established in medical applications.
The Vascutek Ltd. Hybrid Device is produced using established manufacturing and Quality Control methodologies in an ISO 9001 and ISO 13485 certified system. The Hybrid Device is provided sterile for single use only. The method of sterilisation is ethylene oxide.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Hannover, Germany, 30625
- Division of Thoracic and Cardiovascular Surgery, Hannover Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with aneurysm and/or dissection of the aortic arch and/or descending aorta
- Patient must have agreed to participate voluntarily and have signed and dated an Ethics Committee approved Patient Informed Consent
- Patient is able and willing to comply with the protocol and associated follow-up requirements
Exclusion Criteria:
- Patients unfit for open surgical repair involving circulatory arrest
- Endocarditis or active infective disorder of the aorta
- Patients unwilling to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary Safety Endpoint
Time Frame: ≤30 days
|
The primary safety endpoint will be the proportion of subjects free from paraplegia, secondary conversion to conventional open surgical repair and death due to device or procedure related complications ≤30 days post-procedure.
|
≤30 days
|
Primary Effectiveness Endpoint
Time Frame: ≤365 days
|
The primary effectiveness endpoint will be successful aneurysm treatment, defined as a composite endpoint of subjects who have successful delivery and deployment of the Vascutek Hybrid Device at the initial procedure and at ≤365 days post-procedure.
|
≤365 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success
Time Frame: Pre-discharge, 6 and 12 months
|
Technical success is defined as the placement and deployment of a Vascutek Hybrid Device in the absence of mortality, conversion to conventional open surgical repair, failed patency, evidence of an unanticipated distal type I or a type III endoleak on pre-discharge CT scan.
|
Pre-discharge, 6 and 12 months
|
Assessment of Stent Graft Migration and Integrity
Time Frame: Pre-discharge, 6 and 12 months
|
Stent graft migration will be defined as stent graft migration in excess of 10mm which requires secondary intervention.
Structural integrity will be assessed primarily from plain x-ray and CT scan images and will be represented in binomial fashion.
|
Pre-discharge, 6 and 12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HYBRID-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aneurysmal Disease of the Ascending Aorta, the Arch and the Proximal Descending Aorta
-
Datascope Corp.UnknownAneurysmal Disease of the Abdominal Aorta | Occlusive Disease of the Abdominal AortaFrance
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Meshalkin Research Institute of Pathology of CirculationNot yet recruitingthe Strength Properties of the Aorta in Vivo | the Strength Properties of the Aorta in Vitro | Regression Model of Aortic Strength Properties in Vitro and in VitroRussian Federation
-
Xijing HospitalChanghai HospitalCompletedAorta Thoracic Ascending Dissection | Dissection of Descending AortaChina
-
William Cook EuropeCook Group Incorporated; MED Institute, Incorporated; William Cook AustraliaCompletedAortic Dissection Involving the Descending Thoracic AortaItaly, Germany, Australia, Czech Republic, France
-
Vascutek Ltd.Federation of Medical SpecialtiesActive, not recruitingAneurysm Thoracic | Dissection of Thoracic Aorta | Pathology of the Thoracic Aorta | Pseudo-aneurysm, Thoracic | Intramural Haematoma of Thoracic Aorta | Penetrating Ulcer of Aorta (Disorder) | Rupture of the IsthmusFrance
-
Tomsk National Research Medical Center of the Russian...RecruitingAscending Aorta Aneurysm | Dilation of the Ascending AortaRussian Federation
-
Centre Hospitalier Universitaire DijonWithdrawnAneurysm of the Abdominal Aorta
-
Centre Hospitalier Universitaire DijonCompletedAneurysms or Occlusive Disease of the Abdominal AortaFrance
-
Gangnam Severance HospitalCompletedDissecting Aneurysm of the Thoracic Aorta | Chronic Dissecting Aneurysm of Thoracic Aorta | Chronic Nontraumatic Dissection of Thoracic AortaKorea, Republic of
Clinical Trials on Vascutek Hybrid Graft
-
Vascutek Ltd.TerminatedAbdominal Aortic AneurysmUnited Kingdom, Australia, New Zealand, Germany, France, Italy, Spain
-
Vascutek Ltd.Active, not recruitingAbdominal Aortic AneurysmNetherlands, Canada, United Kingdom, Austria, Australia
-
Xijing HospitalChanghai Hospital; Shanghai Zhongshan HospitalUnknown
-
W.L.Gore & AssociatesTerminatedEnd Stage Renal DiseaseUnited States
-
Meshalkin Research Institute of Pathology of CirculationUnknownAortic Insufficiency | Ascending Aorta AneurismRussian Federation
-
Jessa HospitalRecruitingCoronary Artery DiseaseBelgium
-
Erasmus Medical CenterMedtronic; Alrijne HospitalNot yet recruitingIncisional Hernia of Midline of AbdomenNetherlands
-
Lawson Health Research InstituteLondon Health Sciences CentreCompleted
-
Chang Gung Memorial HospitalUnknown
-
University of Roma La SapienzaNot yet recruitingCoronary Artery Disease